TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05554952

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
Study: NCT05817851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
Description: in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
Study: NCT05885022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibreye System
Description: Implantation of a glaucoma device to reduce intraocular pressure
Study: NCT04950374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer Body Lotion
Description: The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lip Moisturizer
Description: The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
Study: NCT06368765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution (ORS)
Description: Participants will be administered the ORS during one of the study visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will be administered water during one of the study visits
Study: NCT05755308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous FMT
Description: Autologous faecal microbiota transplantation by colonoscopy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT
Description: Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
Study: NCT06157281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
Study: NCT06191718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Replacement
Description: Foldax Mitral Valve Replacement
Study: NCT05938985

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires and dry eye tests
Description: Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires and dry eye tests
Description: Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
Study: NCT06395272

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SURA
Description: The motor points are the site of penetration of the motor nerve fibres and the highest concentration of motor plates in the muscle, which when stimulated produce the maximum effective muscle contraction. For 15 minutes and in a comfortable seated position at 90° hip, knee and foot, sustained pressure of 30 seconds each shall be exerted through the output plunger of the proprioceptive stimulus device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURA
Description: The motor points are the site of penetration of the motor nerve fibres and the highest concentration of motor plates in the muscle, which when stimulated produce the maximum effective muscle contraction. For 15 minutes and in a comfortable seated position at 90° hip, knee and foot, sustained pressure of 30 seconds each shall be exerted through the output plunger of the proprioceptive stimulus device.
Study: NCT04808804

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
Study: NCT05309278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
Study: NCT06279325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive stimulation program
Description: * The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face training-explanatory session
Description: The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
Study: NCT04672941

Intervention type: DRUG
Intervention: Tiotropium bromide plus Olodaterol
Description: Tiotropium bromide plus Olodaterol
Study: NCT05895370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-T
Description: Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 500,000IU/m\^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
Study: NCT06458205

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multi-component intervention for smokers
Description: 1. Community-based spirometry pulmonary function tests and result interpretations and health education;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for smokers whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to smokers with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients or asthma patients;~7. To actively include smokers whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than11.1mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \<18.5;~9. Pay-for-population mechanism for medical practitioners.
Study: NCT06542536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monlunabant
Description: Oral monlunabant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monlunabant
Description: Oral monlunabant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monlunabant
Description: Oral monlunabant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (monlunabant)
Description: Oral placebo (monlunabant)
Study: NCT05307848

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06580873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOVATO
Description: HIV-1 medication
Study: NCT05828966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin (hCG)
Description: H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: 4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
Study: NCT06472466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep/eating virtual reality self-help exposure-based intervention
Description: Participants will receive one of two possible interventions:~1. A virtual reality kitchen with foods with different caloric contents. Participants will be invited to explore the environment and interact with the stimuli they feel most comfortable with. Depending on their preference, they will be able to access the virtual kitchen in one of three different conditions: alone, accompanied by a pink elephant (designed to induce positive mood), or accompanied by a reassuring voice that will encourage them to interact with the food and face their fears.~2. A virtual reality bedroom with several objects, some of which will have a neutral valence for people with sleep difficulties, and others that will be related to insomnia, such as a mobile phone, electronic devices and a clock marking 3:00. Participants will be first told to move in the environment and they could not fall asleep. Then, they will receive specific instructions to cope with sleeping difficulties.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep/eating self-help written materials.
Description: Participants allocated to the control condition will be invited to download self-help written materials about eating and sleep difficulties and helpful ways to cope with these.
Study: NCT01438502

Intervention type: DRUG
Intervention: HyperHAES® (hypertonic saline/HES)
Description: After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
Study: NCT05066230

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
Study: NCT05542784

Intervention type: PROCEDURE
Intervention: Modified LERV
Description: Patients routinely underwent LC. The ligature clamp clamps the distal end of the capsule tube. In this case, you need to perform two steps:~Laparoscopic operation: proximal incision, anterograde placement of guide wire into the duodenum. The catheter was removed and the balloon dilated. The balloon was released and removed when the ERCP was initiated for cannulation. After successful ERCP retrograde placement, the anterograde guide wire was pulled out and the gallbladder was removed.~ERCP procedure: After the anterograde guide wire was observed by duodenoscope, duodenal papilla was placed through a retrograde incision along the anterograde guide wire, and a retrograde cannula was inserted into the common bile duct. Remove stones by dragging them with a net basket or/and balloon. Angiography confirmed that there was no filling defect in the extrahepatic bile duct, and ENBD was indwelled.
Study: NCT06236750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIFIX
Description: EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
Study: NCT05776173

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD211
Description: Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
Study: NCT05668533

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene versus PENG Block
Description: 1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).
Study: NCT06192329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot water therapy
Description: On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Warm water immersion
Description: On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
Study: NCT06578403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external microneedling
Description: external micro_needling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive non- surgical periodontal therapy
Description: minimally invasive non- surgical periodontal therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimally invasive non- surgical periodontal therapy
Description: minimally invasive non- surgical periodontal therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimally invasive non- surgical periodontal therapy
Description: minimally invasive non- surgical periodontal therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal micro_needling
Description: internal micro_ needling
Study: NCT06577194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab + IL-2 Combined with Capox
Description: Sintilimab + IL-2 Combined with Capox

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy+IL-2
Study: NCT05203796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous pulsed electrical stimulation (NuEyne 02)
Description: Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
Study: NCT05931042

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
Study: NCT06578533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: The recommended starting dose of Lokelma is 10 g, administered three times a day.~If, at any time during the study, sK is \> 6.5 mEq/L, treatment for acute hyperkalemia will be started following common clinical practice and local protocols, and investigator will consider RAASi / MRA withdrawal, or downtitration. In this case (confirmed sK \> 6.5 mEq/L despite the maximum SZC dose) patient will leave the IP and will be counted as a treatment failure.~If sK is ≤ 3.0 mEq/L, discontinue SZC. The subject should immediately receive appropriate medical intervention.~If sK is between 3.1-5.1 mEq/L, pause SZC and re-evaluate in a week. This one-week SCZ treatment temporary discontinuation can only be applied once; if a new sK value between 3.1-5.1 mEq/L is detected, patient will leave the IP permanently.~Depending on the serum potassium levels at each visit, the dose of SZC will be adjusted.
Study: NCT06575907

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04959981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally
Study: NCT05953337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYE90 Microspheres Treatment
Description: Y90 glass microspheres
Study: NCT05853887

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: iNUDGE
Description: Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: iNUDGE
Description: Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: iNUDGE
Description: Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
Study: NCT04959981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered orally
Study: NCT05911503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Ganciclovir Eye Drops
Description: Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
Study: NCT06079905

Intervention type: OTHER
Intervention: Nonoperative treatment
Description: Nonoperative treatment

Intervention type: OTHER
Intervention: Operative treatment
Description: Operative treatment
Study: NCT06321081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, cetuximab, envafolimab
Description: rechallenge treatment
Study: NCT04517656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~* Samples before the allograft,~* Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~* Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment.
Study: NCT06200454

Intervention type: DEVICE
Intervention: neuromuscular ultrasound of cranial nerves
Description: neuromuscular ultrasound of cranial nerves.

Intervention type: DEVICE
Intervention: neuromuscular ultrasound of cranial nerves
Description: neuromuscular ultrasound of cranial nerves.
Study: NCT04959981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered orally
Study: NCT05332210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection (680mg)
Description: HBM9161 Injection
Study: NCT04973969

Intervention type: OTHER
Group type: OTHER
Intervention: Decapeptyl
Description: diagnosis of predictio value
Study: NCT05138770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets
Description: VC005 Tablets 1、5、10、25、50、100mg single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Tablets Placebo
Description: VC005 Tablets Placebo 1、5、10、25、50、100mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets food effects group
Description: VC005 Tablets qd per period, for two periods